CCHT(SZ:000661) Mei Ri Jing Ji Xin Wen·2026-02-26 13:18Core Viewpoint - Changchun High-tech's stock has surged following the approval of its subsidiary's clinical trial application for GenSci141 ointment, the first drug targeting pediatric micropenis, indicating potential market interest and investment opportunity [1][3]. Group 1: Stock Performance - On February 25, Changchun High-tech closed at 97.26 CNY per share, marking its first limit-up of 2026, and continued to rise on February 26, reaching a peak of 108 CNY [1]. - The company's market capitalization is currently 40.2 billion CNY, with a weekly increase of over 12% [1]. Group 2: Product Development - GenSci141 ointment, developed by Changchun JinSai Pharmaceutical, is a dihydrotestosterone ointment aimed at improving conditions related to pediatric micropenis [5]. - This product is currently in the early stages of development, with no external information available yet [3]. Group 3: Market Context - The treatment of pediatric micropenis faces challenges due to varying diagnostic standards and the need to exclude other structural abnormalities [4]. - There has been no approved medication for this condition until now, highlighting the significance of GenSci141's potential [4]. Group 4: Financial Performance - Changchun High-tech's net profit is projected to decrease by over 90% in 2025, with revenue and net profit expected to decline by 7.55% and 43.01% respectively in 2024 [6]. - The company has been investing heavily in R&D, with expenditures increasing from 1.663 billion CNY in 2022 to an expected 2.690 billion CNY in 2024 [7]. Group 5: Licensing Agreements - In December, Changchun JinSai authorized its subsidiary to enter a licensing agreement for the GenSci098 injection project, which could yield up to 1.365 billion USD in milestone payments [7]. - However, these potential revenues will not impact the company's 2025 performance due to accounting policies and payment timelines [7].